Latest news

• Lundbeck gets US approval for migraine drug at heart of Alder takeover

  The product category has extended with an orally-active CGRP drug in December when Allergan secured FDA approval for  Ubrelvy (ubrogepant), though this isn’t a direct competitor as it is

• Botox strength bolsters Allergan ahead of AbbVie takeover

  Allergan chief executive Brent Saunders said Allergan is entering 2020 with “strong momentum”, helped by approvals such as an FDA green light for new acute migraine therapy Ubrelvy (ubrogepant).

• Lilly launches migraine med Reyvow at $640 per eight-pill pack

  Its closest competitor is Allergan’s Ubrelvy (ubrogepant) – an oral CGRP inhibitor which also has FDA approval in the treatment of acute migraine, with or without aura.

• Allergan gets FDA nod for first oral CGRP drug for migraine

  The US regulator has given a green light to  Ubrelvy (ubrogepant) for acute migraine with or without aura, and Ireland-domiciled Allergan says it intends to launch the drug in the

• Teva’s migraine injection approved in Europe

  The FDA also recently accepted an NDA from Botox developer Allergan, which filed its oral CGRP ubrogepant for the acute treatment of migraine in adults.